Cadila Healthcare inks ZyCoV-D commercialisation agreement with Korean firm

Cadila Healthcare on Wednesday said that it has entered into a manufacturing license and technology transfer agreement for its plasmid DNA-based Covid vaccine, ZyCoV-D, with Enzychem Lifesciences.

Headquartered in Seoul, South Korea, Enzychem Lifesciences is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases.

Cadila will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences. Both CHL and Enzychem believe that this partnership will lead to an estimated manufacturing of 80 million or more doses of the Plasmid DNA vaccine in 2022.